IJBPAS, May, 2026, 15(5): 2114-2129

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

# REVIEW ON THE APPLICATION OF PUSH-PULL OSMOTIC PUMPS IN TARGETED DRUG DELIVERY FOR CHRONIC DISEASE MANAGEMENT

**DYAMESH S, SHEEBA F R*, CHAITRA M AND VARUN S**

Department of pharmaceutics, Mallige college of Pharmacy, #71, Silvepura, Chikkabanavara Post, Bangalore-560090

***Corresponding Author: Dr. Sheeba F R: E Mail: sheebagiles@gmail.com**

**Received 25th Feb. 2025; Revised 24th April 2025; Accepted 16th June 2025; Available online 1st May 2026**

https://doi.org/10.31032/IJBPAS/2026/15.5.10125

## ABSTRACT

Push-Pull Osmotic Pumps (PPOP) have emerged as a promising drug delivery system for managing chronic diseases. These systems offer controlled, sustained, and targeted drug release, addressing the limitations of conventional delivery methods such as poor bioavailability, patient non-compliance, and side effects. PPOP employs a dual-chamber design, with one compartment containing the drug and the other an osmotic agent, facilitating precise and prolonged release through osmotic pressure. This review explores the principles, design, and mechanisms of PPOP, emphasizing its application in chronic disease management, including diabetes, cardiovascular diseases, and neurological disorders. The ability of PPOP to maintain consistent plasma drug concentrations enhances therapeutic outcomes and minimizes adverse effects. Additionally, recent advancements, such as incorporating nanoparticles and biodegradable materials, have further optimized PPOP for targeted delivery. This paper highlights the potential of PPOP in revolutionizing chronic disease treatment while identifying challenges and future research directions to maximize its clinical utility.

**Keywords: Push-Pull Osmotic Pumps, chronic disease management, bioavailability, dual-chamber**

## INTRODUCTION

Push-Pull Osmotic Pumps are advanced drug delivery systems designed to provide drug controlled and sustained release. They are especially useful for poorly soluble drugs or drugs that require extended, specific therapeutic effect **[1]**. They are based on the mechanism of osmotic pressure, where they use the osmotic

pressure difference between the inner drug reservoir and the outside environment to control uniform and reliable drug release, independent of gastrointestinal conditions such as pH or ingestion of food **[2]**. The internal core of a PPOP consists of two main parts: the drug layer and the push layer. The drug layer includes active pharmaceutical ingredients (APIs) along with excipients like solubilizers, osmotic agents, and stabilizers that aid in drug dispersion **[3]**. The push layer is made of swelling polymers (e.g., polyethylene oxide or sodium carboxymethyl cellulose) and osmogens (e.g., sodium chloride, mannitol), which swell upon water intake and push the drug out**[4]**.This dual-layered core is surrounded by a semipermeable membrane made of modified cellulose acetate and plasticizers, which allows water to pass through while preventing medication leakage. The thickness and permeability of the membrane have a direct impact on water input and, consequently, medication release rates. A laser-drilled hole on the surface serves as an exit route for the medication. The size and location of this hole are crucial to preventing dosage dumping and ensuring uniform medication release **[5]**.

The mechanism of action is based on an interaction between osmosis and hydraulic pressure. Water enters via the semipermeable membrane, activating the push layer and creating pressure that pushes the medication out through the aperture **[6]**. This method results in a zero-order release profile, which ensures consistent medication delivery across time. The mechanism involves five steps:

Step 1: Initial Water Uptake

Step 2: Activation of the Push Layer

Step 3: Drug Layer Dissolution or Suspension Formation

Step 4: Drug Release through the Orifice

Step 5: Sustained and Controlled Release **[7]**.

The idea of osmotic drug administration was first proposed in the 1950s. The Rose-Nelson pump, the first osmotic pump created for veterinary use, was created in 1955 by Rose and Nelson. It introduced the fundamental idea of osmotic control in drug administration, notwithstanding its primitiveness **[8]**. These designs were later improved for human usage, increasing flexibility, patient compliance, and efficacy **[9]**.

**Advantages of Push-Pull Osmotic Pumps in Drug Delivery**

Push-Pull Osmotic Pumps offer a range of advantages in drug delivery due to their innovative design and controlled-release mechanisms. Here are their key benefits.

- PPOPs ensure a predictable and controlled release rate of the drug over an extended period, independent of gastrointestinal (GI) pH, motility, or food intake.

- They reduce the need for frequent dosing, improving patient adherence.
- Suitable for delivering a wide range of drugs, including those with poor solubility, high potency, or narrow therapeutic windows **[10]**.
- Capable of delivering both water-soluble and water-insoluble drugs by incorporating solubility-enhancing excipients.
- Maintains steady plasma drug concentrations, avoiding peaks and troughs that could lead to side effects or reduced efficacy **[11, 12]**.

**Design and formulation of push-pull osmotic pumps**




**Figure 1: Structure of push-pull osmotic pumps**

The design and formulation of PPOPs involve several critical components and steps to ensure controlled, sustained drug release. Below is a detailed overview of the design, formulation, and essential considerations for developing an effective PPOPs-based drug delivery system [**13**]. The basic design of a Push-Pull Osmotic Pump consists of two main compartments: the push layer and the pull layer, along with an osmotic membrane and an exit port.

Several factors influence the drug release profile in PPPOP affecting the rate, consistency, and duration of the drug release. These factors include the properties of the pump components (push layer, pull layer, osmotic membrane) and the physiological conditions under which the pump operates. Here are the key factors that influence drug release profiles in PPOPs:

- Composition and Properties of the Push Layer
- Composition and Properties of the Pull (Drug) Layer
- Properties of the Osmotic Membrane
- Exit Port Size and Design
- Physiological Conditions
- Drug Dose and Therapeutic Window
- Environmental Factors **[14, 15]**.

**PPOP'S IN CHRONIC DISEASES MANAGEMENT**

PPOPs are highly effective drug delivery systems for managing chronic diseases due to their ability to provide controlled,

sustained, and predictable drug release **[16]**. Chronic diseases often require consistent drug plasma levels over extended periods, which PPOPs can achieve, enhancing therapeutic outcomes and patient compliance.

## CARDIOVASCULAR DISEASES MANAGEMENT

PPOPs play a significant role in the management of cardiovascular diseases (CVDs) by ensuring controlled and sustained release of drugs **[17]**. Cardiovascular conditions such as hypertension, angina, arrhythmias, and heart failure often require long-term and precise drug delivery to maintain efficacy while minimizing side effects. The following are the key applications of PPOPs in cardiovascular disease management:

### 1. Hypertension

PPOPs provide a useful approach for the control of hypertension through the delivery of antihypertensive medication in a regulated and prolonged fashion **[18]**. This action provides the consistent plasma drug concentrations, which is essential for 24-hour blood pressure regulation and for minimizing cardiovascular hazards. Short-half-life drugs, including calcium channel blockers nifedipine, amlodipine, and felodipine, are particularly favourably influenced by PPOPs, which ensure constant vasodilation and stability of blood pressure **[19]**. Early morning blood pressure peaks, which are known to raise the risk of cardiovascular events, are prevented by PPOPs with stable drug plasma levels. In addition, they avoid the rapid peak concentrations that tend to lead to dose-dependent side effects. The once-daily dosing facilitated by PPOPs also enhances compliance in long-term hypertension treatment **[20]**.

### 2. Angina Pectoris

In angina pectoris, PPOPs facilitate sustained release of drugs, minimizing frequency and severity of ischemic attacks. This is particularly helpful for isosorbide mononitrate and dinitrate, which are short-half-life drugs that usually need to be administered often **[21]**. PPOPs minimize nitrate tolerance by preventing high plasma peaks that result in decreased efficacy over a period. In addition, they are useful in the management of morning angina, which is precipitated by circadian changes in heart rate and blood pressure **[22]**.

### 3. Arrhythmia

Arrhythmias require continuous drug levels to prevent fluctuations that can lead to toxicity or therapeutic failure **[23]**. PPOPs offer an answer by sustaining controlled and consistent plasma levels of antiarrhythmic drugs. These drugs tend to have low therapeutic windows, where slight changes in plasma concentration could cause severe adverse events such as proarrhythmic **[24]**. In atrial fibrillation, PPOPs aid in rate control by releasing drugs in a sustained

manner and preventing complications such as stroke or heart failure **[25]**. They also aid in long-term rhythm control and prevent recurrence of arrhythmic events **[26]**. For ventricular arrhythmias such as VT or VF, PPOPs provide life-saving prolonged drug delivery. In addition, their chronotherapeutic potential enables coordination with circadian peaks in arrhythmic activity, e.g., those in the early morning **[27]**.

**4. Heart Failure**

Treatment of heart failure depends on drugs that need steady-state concentrations to control symptoms and arrest disease progression **[28]**. PPOPs allow for extended and consistent release of medications such as beta-blockers (metoprolol, bisoprolol, carvedilol), ACE inhibitors (enalapril, ramipril), and ARBs (losartan, valsartan). Simplifying complicated regimens through once-daily dosing enhances compliance in patients with comorbidities **[29]**. Through the elimination of peaks and troughs, PPOPs also minimize the risk of side effects such as hypotension and hyperkalaemia **[30]**. Their chronotherapeutic suitability for symptom control facilitates improved symptom control in accordance with circadian rhythms of dyspnoea or edema **[31]**, and their sustained drug release can prevent pathological cardiac remodelling **[32]**.

**Table 1: Research on PPOP drug delivery for the treatment of cardiovascular diseases**

| API | Dosage form | Reference |
|---|---|---|
| Treprostinil diethanolamine | Single-Effect Osmotic Pump | 28 |
| Lercanidipine | Dual-Effect Osmotic Pump | 30 |
| Oxybutynin chloride | Push-Pull Osmotic Pumps | 31 |

**DIABETES MELLITUS DISEASES MANAGEMENT**

Push-Pull Osmotic Pumps present a novel solution for managing diabetes mellitus by offering controlled, sustained drug release, addressing glycemic variability, complex dosing schedules, and patient adherence challenges. They maintain consistent plasma drug levels, enhancing the efficacy of medications such as metformin, sulfonylureas (e.g., glimepiride), and DPP-4 inhibitors (e.g., sitagliptin), thereby reducing postprandial spikes and minimizing hypoglycemia risks. PPOPs also support insulin sensitizers like pioglitazone by providing prolonged action without fluctuations **[33]**. Combination formulations (e.g., metformin with sitagliptin or pioglitazone with glimepiride) are made more convenient, improving compliance. PPOPs can align drug release with circadian rhythms, targeting the dawn phenomenon for better 24-hour glucose control **[34]**. They reduce gastrointestinal side effects and have future potential in long-acting delivery of injectables like GLP-1 receptor agonists **[35]**. With once-daily or less frequent dosing, PPOPs help stabilize glucose levels and prevent complications like nephropathy and neuropathy, marking a major advance in diabetes care **[36]**.

**Table 2: Research on PPOP drug delivery for the treatment of diabetes mellitus**

| API | Dosage form | Reference |
|---|---|---|
| Glipizide | Push-Pull Osmotic Pumps | 32 |
| Metformin HCl | Dual-Effect Osmotic Pump | 35 |
| Pioglitazone HCl | Push-Pull Osmotic Pumps | 36 |

## NEUROLOGICAL DISORDER MANAGEMENT

Push-Pull Osmotic Pumps (PPOPs) represent a novel drug delivery system of special interest in neurological diseases where controlled, long-term, and consistent drug delivery is of essence. Neurological disorders such as Parkinson's disease, Alzheimer's disease, epilepsy, multiple sclerosis, and chronic pain find advantage in the capability of PPOPs to provide steady plasma drug levels, minimize side effects, and maximize patient compliance **[37]**. In Parkinson's disease, PPOPs assist in delivering levodopa or dopamine agonists continuously, lessening motor fluctuations and peak-dose dyskinesia. In Alzheimer's disease, they facilitate sustained delivery of cholinesterase inhibitors (e.g., donepezil) and NMDA antagonists (e.g., memantine), maintaining cognitive function and hindering disease advancement **[38]**. In epilepsy, PPOPs supply constant levels of AEDs such as carbamazepine, lamotrigine, and levetiracetam, lessening seizure risk and toxicity **[39]**. In chronic neurological pain, PPOPs release drugs like pregabalin or opioids in a controlled fashion, reducing addiction and tolerance risk. In multiple sclerosis, they help to deliver immunomodulators like fingolimod and dimethyl fumarate, which may decrease relapse rates **[40]**. The ability of PPOPs to sustain narrow therapeutic margins enables once-daily administration, enhancing compliance. They also facilitate chronotherapy, scheduling drug release with circadian symptom patterns, for example, and early morning stiffness in Parkinson's or nighttime seizures **[41]**. PPOPs hold potential for future uses such as biologics, neurotrophic factors, or gene therapies, expanding their horizon in the management of progressive neurodegenerative illnesses such as Huntington's disease or ALS **[42]**. PPOPs are therefore turning out to be a revolutionary intervention in neurological management, improving outcomes and quality of life in patients**[43]**.

**Table 3: Research on PPOP drug delivery for the treatment of neurological disorder**

| API | Dosage form | Reference |
|---|---|---|
| Cyclobenzaprine | Single-Effect Osmotic Pump | 40 |
| Hydromorphone | Dual-Effect Osmotic Pump | 42 |
| Carbamazepine | Single-Effect Osmotic Pump | 43 |

**CANCER THERAPEUTICS MANAGEMENT**

Push-Pull Osmotic Pumps are a future potential in cancer therapeutics with controlled and extended release of the drug to manage issues like toxicity, poor efficacy, and poor patient compliance. In cancer chemotherapy, it is crucial to provide consistent therapeutic concentrations of the drug over an extended period for effective outcomes. PPOPs provide this by providing anticancer drugs such as chemotherapeutics, targeted therapies, immunotherapies, gene therapies, and oncolytic viruses in a continuous, predetermined way **[44]**. Classic chemotherapeutics such as paclitaxel, doxorubicin, and cisplatin are effective but cause significant side effects by virtue of high peak concentrations. PPOPs overcome these toxic effects by providing uniform drug levels, enhancing tolerability, quality of life, and patient compliance. Targeted agents like imatinib and trastuzumab also gain from the stable delivery offered by PPOPs, avoiding drug resistance and ensuring maximal efficacy through optimal concentration maintenance **[45]**. Immunotherapies such as checkpoint inhibitors like pembrolizumab and cytokines like interleukin-2 need to be dosed carefully to prevent immune-related adverse effects. PPOPs modulate the release of these agents, compromising immune activation and reducing toxicity **[46, 47]**. New therapies like gene therapy, oncolytic viruses, and siRNAs demand sustained, localized exposure, which PPOPs can facilitate through sustained release within the tumour environment. Combined with nanoparticle-based systems, PPOPs enhance tumour specificity and enable multi-drug combination regimens for better efficacy and to counter resistance **[48]**.Also, PPOPs minimize the dosing frequency, an important advantage for long-term or palliative cancer patients. This enhances convenience and compliance, a revolutionary way of treating cancer **[49, 50]**.

**Table 4: Research on PPOP drug delivery for the treatment of cancer**

| API | Dosage form | Reference |
|---|---|---|
| Leuprolide acetate | Single-Effect Osmotic Pump | 48 |
| ER Hydromorphone | Dual-Effect Osmotic Pump | 50 |

## PHARMACOKINETICS AND PHARMACODYNAMICS OF PUSH-PULL OSMOTIC PUMPS

Push-Pull Osmotic Pumps are sophisticated drug delivery systems designed to provide controlled, sustained, and predictable drug release over extended periods. Understanding the pharmacokinetics (PK) and pharmacodynamics (PD) of PPOPs is crucial for optimizing their use in therapeutic applications, including the

management of chronic diseases, cancer, and neurological disorders **[51]**.

**Pharmacokinetics of PPOPs**

Pharmacokinetics involves the study of the absorption, distribution, metabolism, and excretion (ADME) of drugs. In the case of PPOPs, the key pharmacokinetic features are related to the controlled drug release they provide.

1. **Absorption**: PPOPs are designed to release drugs directly into the bloodstream or target tissue through a semipermeable membrane. The drug is typically dissolved in a core compartment within the pump, which is in contact with the surrounding biological environment. As water enters the pump through osmotic pressure, the drug is pushed out at a constant rate through the pump's delivery orifice. This mechanism minimizes the fluctuations in drug concentration that often occur with oral or injection-based therapies. Since PPOPs are intended for systemic delivery, they bypass the gastrointestinal tract, leading to more predictable absorption compared to oral drugs, where first-pass metabolism can lead to inconsistent bioavailability **[52]**.
2. **Distribution**: The distribution of the drug released by PPOPs depends on factors such as the molecular characteristics of the drug (lipophilicity, solubility, etc.) and the properties of the surrounding tissues. PPOPs can be designed to target specific tissues, such as the tumour site in cancer therapy or the central nervous system in neurological treatments. The controlled release ensures that the drug reaches therapeutic concentrations in the desired tissue, potentially improving the drug's efficacy and reducing systemic side effects **[53]**.
3. **Metabolism**: PPOPs do not directly affect drug metabolism but, by providing continuous drug delivery, they can help maintain drug concentrations within a therapeutic window. This consistent delivery ensures that the drug is available for metabolism over a prolonged period, which can be important for drugs with narrow therapeutic windows. The rate of metabolism is still influenced by factors like liver function, enzyme activity, and drug interactions **[54]**.
4. **Excretion**: The excretion of drugs delivered via PPOPs follows the same general pathways as any other drug, primarily through the kidneys and liver. Since the drug is released

in small, controlled doses, the peak concentrations in the plasma are lower compared to bolus injections or oral doses. This often leads to a reduction in renal or hepatic overload and may minimize adverse effects related to drug clearance.

5. **Sustained Release**: One of the most significant pharmacokinetic advantages of PPOPs is their ability to provide a zero-order or near-zero-order release of the drug. This means that the drug is released at a constant rate over an extended period, ensuring a stable plasma concentration that minimizes peak-trough fluctuations that may lead to drug toxicity or subtherapeutic effects. The rate of drug release depends on the osmotic gradient between the core and the surrounding environment, as well as the properties of the drug itself **[55]**.

**Pharmacodynamics of PPOPs**

Pharmacodynamics refers to the study of the effects of drugs on the body, including the mechanisms through which they exert their therapeutic effects and the relationship between drug concentration and effect. The pharmacodynamics of drugs delivered via PPOPs are influenced by the steady and controlled release profile provided by the pumps.

1. **Therapeutic Effect**: Push-Pull Osmotic Pumps (PPOPs) have a number of pharmacodynamic benefits by sustaining drug concentrations within the therapeutic range for long periods. The stability in turn produces steady and optimal treatment effects, particularly in chronic illnesses such as hypertension, diabetes, and cancer. In cancer treatment, for example, the sustained drug concentration improves cytotoxicity against tumor cells and minimizes damage to normal tissue **[56]**.
2. **Targeted Delivery**: PPOPs also facilitate drug targeting, where the drug is delivered directly at the location of action, e.g., within tumors or inflamed tissue. This maximizes local efficacy with minimal systemic side effects, rendering the treatments more specific and less toxic**[57]**
3. **Dose-Dependent Effects**: They are well suited for narrow therapeutic index drugs such as immunosuppressants or chemotherapy drugs since they have a constant bloodstream concentration, thus lowering the risks of underdosing or toxicity. This results in more predictable and safer clinical outcomes **[58]**.

4. **Minimized Side Effects**: Another principal benefit is reduction of side effects. The steady release of PPOPs avoids plasma level spikes characteristic of unwarranted adverse effects like nausea or myelosuppression, typical in cancer therapies **[59]**.
5. **Chronotherapy**: PPOPs also facilitate chronotherapy, coordinating drug release with disease symptom circadian patterns for instance, dosing for Parkinson's or cancer therapy when symptoms peak thereby optimizing drug efficacy at critical moments.
6. **Synergistic Effects**: Lastly, PPOPs enable synergistic action via concurrent administration of more than one agent, like in combination chemotherapy. This eliminates fluctuating plasma concentrations and maximizes overall effect by providing stable drug exposure **[60]**.

**CHALLENGES AND LIMITATIONS OF PPOP'S**

The push-pull osmotic pump has several challenges and limitations, including complex manufacturing and design requirements, high production costs and limited drug compatibility due to specific physical chemical properties. The advanced technology and materials required to create PPOP make them more expensive than traditional drug distribution methods, and the cost of development and regulatory approval can limit their widespread adoption. Additionally, PPOPs are subject to mechanical failure, limited control over drug release in changing environment, and patient compliance and acceptance issues. Regulatory approval is complex, including both drug and device regulations, and long - term use may require periodic maintenance or replacement, adding costs and logical burden. If the osmotic system fails, there is also a risk of overdose or underdose, and limited flexibility in dose regimens may not correspond to all treatment needs. In addition, drug stability and shelf-life can be affected by pump content, and some drugs may be low with time, especially if they are highly sensitive to environmental factors. Overall, these challenges and boundaries can affect the effectiveness of PPOP in some medical contexts, ease of use and viability **[61, 62]**.

**FUTURE PROSPECTIVES**

The future of Push-Pull Osmotic Pumps (PPOPs) in drug delivery is very promising, with the potential to revolutionize treatment approaches in many areas of medicine. PPOPs will be at the forefront of personalized medicine, allowing for customized drug delivery according to individual patient profiles, such as genetic information and disease biomarkers. Personalized drug delivery can improve

dosing precision, enhance treatment efficacy, and minimize side effects. One notable development is the creation of "smart" PPOPs that incorporate sensors and feedback systems, allowing real-time drug release modification based on a patient's physiological status. This development addresses special utility in controlling dynamic diseases such as diabetes, cardiovascular, and neurological diseases **[63]**. Convenience is enhanced by integration with wearable technology like glucose levels and heart rate monitoring. Technological advancements in biocompatible materials and shrinking device size make PPOPs increasingly comfortable to use for prolonged periods or implants. Multi-drug delivery capacity is on the verge of offering treatment for many diseases at one time, with fewer pills required. With advancements in gene and cell therapy, PPOPs may provide long-term delivery of genetic material or genetically engineered cells to enhance treatments for genetic diseases, autoimmune disorders, and cancer. Next-generation PPOPs might include on-demand release mechanisms and targeted delivery to target tissues, like tumors, for more precise treatment and reduced systemic impact. With changing regulatory support and affordable production, PPOPs are increasingly accessible worldwide. These technologies will define a future of responsive, efficient, and patient-focused therapies, transforming chronic disease and cancer care **[64]**.

## CONCLUSION

Push-Pull Osmotic Pumps are a revolutionary advance in site-specific drug delivery, providing controlled, sustained, and accurate drug release. Their structure enables uniform drug levels over long durations, minimizing dosing frequency and enhancing patient compliance essential for the treatment of chronic diseases such as diabetes, cardiovascular diseases, neurological disorders, and cancer. By utilizing osmotic pressure to control drug release, PPOPs offer a consistent therapeutic effect, unaffected by external physiological parameters. The combination of PPOPs with sophisticated technologies, i.e., smart sensors and wearable devices, increases their versatility. These smart systems allow for real-time adaptability of drug delivery according to the physiological status of the patient, which is particularly advantageous for conditions that have changing requirements for medication. Additionally, the ability of PPOPs to selectively target specific tissue, for example, tumours, reduces systemic side effects while increasing therapeutic efficacy. With ongoing research and development, PPOPs are likely to become increasingly more advanced, including enhanced biocompatible materials, increased shelf life, and controllable drug release profiles.

Even with existing production challenges, economic concerns, and maintenance requirements of devices, a bright future can be predicted for PPOPs. They stand to revolutionize the treatment and management of chronic diseases through optimized, individualized, and streamlined treatment solutions and ultimately better outcomes and improved patient quality of life.

**REFERENCE**


**[1]** Zentner G, McClelland G, Sutton S. Controlled porosity solubility and resin modulated osmotic drug delivery systems for release of diltiazem hydrochloride. J Control Release. 1991;16(1-2):237-43.

**[2]** European Medical Agency. Database of medicines [Internet]. London: European Medical Agency;1995http://www.ema.europa.eu/ema/index.jsp

**[3]** US National Library of Medicine. DailyMed [Internet]. Bethesda (MD): National Library of Medicine (US) ;2013. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4a5762c6-d7a2-4e4c-10b7-832b36fa5f4

**[4]** Kumaravelrajan R, Narayanan N, Suba V. Development and evaluation of controlled porosity osmotic pump for Nifedipine and Metoprolol combination. Lipids Health Dis. 2011;10:51.

**[5]** Usha Sri T, Vooturi R, Vishnu P, Babu KN. Formulation and evaluation of controlled porosity osmotic drug delivery system of Metoprolol succinate. Int J Pharm. 2014; 4(4): 246–55.

**[6]** Li X, Jasti BR. Osmotic controlled drug delivery systems. In: Li X, Jasti BR, editors. Design of controlled release drug delivery systems. New York: McGraw-Hill; 2006. p. 203–29.

**[7]** Rastogi SK, Vaya N, Mishra B. Osmotic pump: a novel concept in rate controlled oral drug delivery. East Pharm. 1995; 38:79–82.

**[8]** Rose S, Nelson JF. A continuous long-term injector. Aust J Exp Biol. 1955; 33:415–21.

**[9]** Eric A, Ashok V, John H, Sai B, William P. Surgery controlled release therapeutic device or system implanted dynamic device or system. US Patent US20110184389. 2011.

**[10]** Wright JC, Johnoson RM, Yum SI. Duros osmotic pharmaceutical systems for parenteral and site directed therapy. Drug Deliv Technol. 2003; 3:3–11.

**[11]** Theewes F. Elementary osmotic pump. J Pharm Sci. 1975; 4(12):1987–91.

**[12]** Rawat A, Prabakaran D, Singh P, Kanaujia PJK, Vyas SP. Modified push pull osmotic system for simultaneous delivery of theophylline and salbutamol. Int J Pharm. 2004;

284:95–108.

**[13]** Srenivasa B, Kumar NR, Murthy KVR. Development and in vitro evaluation of osmotically controlled oral drug delivery system. East Pharm. 2001; 22.

**[14]** Zentner GM, Rork GS, Himmelstein KJ. Controlled porosity osmotic pump. US Patent 4968507; 1990.

**[15]** Padma Priya S, Ravichandram V, Suba V. A review on osmotic drug delivery system. Int J Res Pharm Biomed Sci. 2013; 4(3):810–21.

**[16]** Dong L, Wong P, Espinal S. Loros hardcap: a new osmotic delivery system for controlled release of liquid formulations. In: Proceedings of the International Symposium on Controlled Release of Biomedical Materials; 2001; San Diego.

**[17]** Sareen R, Jain N, Kumar D. An insight to osmotic drug delivery. Curr Drug Deliv. 2012; 9(3):285–96.

**[18]** Theewes F, Wong PSL, Burkoth TL, Fox DA, Bicek PR. Colonic drug absorption and metabolism. In: Marcel Decker, editor. New York: Marcel Decker; 1993. p. 137–58.

**[19]** Lee HB, Liu L, Ku J, Khang G, Lee B, Rhee JM. Nifedipine controlled delivery sandwiched osmotic tablet system. J Control Release. 2000; 68:145–56.

**[20]** Liu L, Wang X. Solubility modulated monolithic osmotic pump tablet for atenolol delivery. Eur J Pharm Biopharm. 2008; 68(2):298–302.

**[21]** Thakor RS, Majmudar FD, Patel JK, Rajput GC. Osmotic drug delivery systems current scenario. J Pharm Res. 2010; 34:771–5.

**[22]** Schultz P, Kleinebudde P. A new multiparticulate delayed release system. Part I: Dissolution properties and release mechanism. J Control Release. 1997; 47:181–9.

**[23]** Ramdan MA, Tawashi R. The effect of hydrodynamic conditions and delivery orifice size on the rate of drug release from elementary osmotic pump system. Drug Dev Ind Pharm. 1987; 13(2):235–48.

**[24]** Arora S, Ali J, Ahuja A, Baboota S, Qureshi J. Pulsatile drug delivery systems: an approach for controlled drug delivery. Indian J Pharm Sci. 2006; 68(3):295–300.

**[25]** Godbillion JH, Gerardin A, Richard J, Leroy D, Moppert J. Osmotically controlled delivery of metoprolol in man: in vivo performance of OROS system with different duration of drug release. Br J Clin Pharmacol. 1985; 19(Suppl 1):69S–76S.

**[26]** Fix J. Encyclopedia of controlled drug delivery. Vol. 2. New York: John Wiley and Sons; 1985. p.700.

**[27]** Kaushal AM, Garg S. An update on osmotic drug delivery patents. Pharm

Technol. 2003; 27:38–44.

**[28]** Parmar NS, Vyas SK, Jain NK. Advances in controlled and novel drug delivery. New Delhi: CBS Publishers; 2008. p.22–31.

**[29]** Kaushal AM, Garg S. An update on osmotic drug delivery patents. Pharm Technol. 2003; 27:38–44.

**[30]** Bhatt PP. Osmotic drug delivery systems for poorly soluble drug. The Drug Delivery Companies.

**[31]** Parmar NS, Vyas SK, Jain NK. Advances in controlled and novel drug delivery. New Delhi: CBS Publishers and Distributors; 2001. p.18–39.

**[32]** Eckenhoff C, Yum SI. The osmotic pump: novel research tool for optimizing drug regimen. Biomaterials. 1981; 2:89–97.

**[33]** Verma S, Saini S, Rawat A, Kaul M. Formulation, evaluation and optimization of osmotically controlled colon targeted drug delivery system. J Pharm Sci Res. 2011; 3(9):1472–85.

**[34]** Baviskar DT, Jain DK. Novel drug delivery system. 2nd ed. Pune: Nirali Prakashan; 2015. p.2.1–2.7.

**[35]** Indian Pharmacopoeia. 6th ed. Ghaziabad: Indian Pharmacopoeia Commission; 2010. p.187–98.

**[36]** Patel H, Patel UD, Kadikar H, Bhimani B, Daslaniya D, Patel G. Formulation and evaluation of controlled porosity osmotic pump tablets of glimepiride. Int J Drug Deliv. 2012;4(1):113–24.

**[37]** Ali M, Senthil K, Parthiban S. Formulation and evaluation of controlled porosity osmotic tablets of prednisolone. Int J Pharm. 2013; 3(2):70–8.

**[38]** Jadav MM, Teraiya SR, Patel KN, Patel BA. Formulation and evaluation of oral controlled porosity pump tablet of zaltoprofen. Int J Pharm Res Sci. 2012; 1(2):254–67.

**[39]** Jadav MM, Teraiya SR, Patel KN, Patel BA. Formulation and evaluation of oral controlled porosity pump tablet of zaltoprofen. Int J Pharm Res Sci. 2012; 1(2):254–67.

**[40]** Wang J. Controlled porosity osmotic pump tablet of high permeable drugs and the preparation method thereof. WO Patent No. 2008052417; 2008.

**[41]** Ruddy S, Debusi L, Storey D. Osmotic controlled release drug delivery device. EP Patent No. 12278008A1; 2001.

**[42]** Athayde AL, Faste RA, Horres CR Jr, Low TP. Controlled release osmotic pump. US Patent No. 5672167; 1997.

**[43]** Haslam JL, Rork GS. Controlled porosity osmotic enalapril pump. Merck & Co. Inc. WO Patent No. 1994001093; 1994.

**[44]** Haslam JL, Rork GS. Controlled porosity osmotic pump. Merck & Co. Inc. EP Patent No. 0309051; 1992.

**[45]** Haslam JL, Rork GS. Controlled

porosity osmotic pump. Merck & Co. Inc. CA Patent No. 1320885; 1991.

**[46]** Himmelstein K. Controlled porosity osmotic pump. CA Patent No. 1266827A; 1990.

**[47]** Zentner GM, Rork GS, Himmelstein KJ. Controlled porosity osmotic pump. Merck & Co. Inc. EP Patent No. 0169105; 1986.

**[48]** Madhavi BB, Nath AR, Banji D, Ramalingam R, Madhu MN, Kumar DS. Osmotic drug delivery system: a review. Pharmakine. 2009; 2:5–14.

**[49]** Sastry SV, DeGennaro MD, Reddy IK, Khan MA. Atenolol gastrointestinal therapeutic system. Part 1: Screening of formulation variables. Drug Dev Ind Pharm. 1997; 23(2):157–65.

**[50]** Verma RK, Krishna DM, Garg S. Formulation aspects in the development of osmotically controlled oral drug delivery systems. J Control Release. 2002; 79:7–27.

**[51]** Patel P, Panchal A, Ghedia T, Christia V. Formulation development and optimization of controlled porosity osmotic pump of propranolol hydrochloride. J Pharm Cosmetol. 2011; 1(5):7–14.

**[52]** Pritam K, Jain M, Patel P. Novel swellable porous osmotic pump drug delivery system. IN Patent No. 2007MU1469A.

**[53]** Harnishpatel. Formulation and evaluation of controlled porosity osmotic pump tablets of glimepiride. Int J Drug Deliv. 2012; 4:113–24.

**[54]** Rao P, Geetha M, Purushothama N, Sanki U. Optimization and development of swellable controlled porosity pump tablet for theophylline. Trop J Pharm Res. 2009; 8(3):247–55.

**[55]** Mahalaxmi R. Enhancement of dissolution of glipizide from controlled porosity osmotic pump using a wicking agent and a solubilising agent. Int J Pharm Tech Res. 2009; 1(3):705–11.

**[56]** Makhija S, Vavia P. Controlled porosity osmotic pump-based controlled release systems of pseudoephedrine. I: Cellulose acetate as a semipermeable membrane. J Control Release. 2003; 89:5–18.

**[57]** Patel P. Recent patents in controlled porosity osmotic pump. Recent Pat Drug Deliv Formul. 2013; 7:66–72.

**[58]** Santus G, Baker RW. Osmotic drug delivery: a review of the patent literature. J Control Release. 1995; 35:1–21.

**[59]** Higuchi T, Leeper HM. Osmotic disperser. US Patent No. 3,732,865; 1973.

**[60]** Higuchi T, Leeper HM. Improved osmotic dispenser employing magnesium sulphate and magnesium chloride. US Patent No. 3,760,804; 1973.

**[61]** Higuchi T. Osmotic dispenser with collapsible supply container. US Patent No. 3,760,805; 1973.

**[62]** Higuchi T, Leeper HM. Osmotic disperser with means for dispensing active agent responsive to osmotic gradient. US Patent No. 3,995,631; 1976.

**[63]** Prabakaran D, Singh P, Kanaujia P, Vyas S. Effect of hydrophilic polymers on the release of diltiazem hydrochloride from elementary osmotic pumps. Int J Pharm. 2003; 259:173–9.

**[64]** Ahuja N, Kumar V, Rathee. Osmotic controlled release oral delivery system: an advanced oral delivery form. Pharma Innov. 2012; 1(7):116–24.